New research suggests that an off-the-market pain reliever called indoprofen may be a starting point for finding a new drug to treat spinal muscular atrophy (SMA), a devastating childhood neurological disorder.

The discovery of the linkage between indoprofen and SMA resulted from the National Institute of Neurological Disorders and Stroke (NINDS)-sponsored Drug Screening Consortium, which screened a collection of 1040 clinically approved drugs for possible activity against amyotrophic lateral sclerosis and other neurodegenerative disorders in 2001 and 2002.
Read the full press release